Ivermectin and Gynecologic Cancer: What are the data?
•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to ef...
Uloženo v:
| Vydáno v: | Gynecologic oncology reports Ročník 60; s. 101803 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Elsevier Inc
01.08.2025
Elsevier |
| Témata: | |
| ISSN: | 2352-5789, 2352-5789 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | •Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.•We have not assessed ivermectin’s safety and efficacy in gynecologic cancers.•We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers. |
|---|---|
| AbstractList | •Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.•We have not assessed ivermectin’s safety and efficacy in gynecologic cancers.•We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers. |
| ArticleNumber | 101803 |
| Author | Mujumdar, Vaidehi Smith, Lindsey Chippendale Musa, Fernanda Huang, Marilyn |
| Author_xml | – sequence: 1 givenname: Vaidehi orcidid: 0000-0001-5687-6667 surname: Mujumdar fullname: Mujumdar, Vaidehi organization: Atrium Health Levine Cancer Institute, 1021 Morehead Drive, Suite 2100, Charlotte, NC 28202, USA – sequence: 2 givenname: Marilyn surname: Huang fullname: Huang, Marilyn organization: University of Virginia School of Medicine, P.O. Box 800712, Charlottesville, VA 22908, USA – sequence: 3 givenname: Lindsey Chippendale surname: Smith fullname: Smith, Lindsey Chippendale organization: University of Virginia Health, 1215 Lee Street, Charlottesville, VA 22903, USA – sequence: 4 givenname: Fernanda surname: Musa fullname: Musa, Fernanda email: Fernanda.Musa2@Swedish.org organization: Providence-Swedish Cancer Institute, 1101 Madison St Suite 1500, Seattle, WA 98104, USA |
| BookMark | eNqFkNtKw0AQhhepYK19Aa_yAql7TDZFEClaC4I3ipfLHibtxjQrm1Do25sYEfFCr2b44fuZ-c7RpAkNIHRJ8IJgkl1Vi22IsKCYiiGQmJ2gKWWCpiKXxeTHfobmbVthjInALM_EFInNAeIebOebRDcuWR8bsKEOW2-TlW4sxGXyutNdoiMk3Q4Spzt9c4FOS123MP-aM_Ryf_e8ekgfn9ab1e1jahmnXSpJyQXjhpe44BwwL_IM25KDwcZJxnLBjXOE8wI4ldwYLvocG2ux00QUbIY2Y68LulLv0e91PKqgvfoMQtwqHTtva1C6yERGmCEaOJfUSIqdK4mRkuSCWN130bHLxtC2EcrvPoLV4FFVavCoBo9q9NhD1yME_ZcHD1G11kOvxfnYS-vP8H_jy1-4rX3jra7f4Pgf_AGZpI4r |
| Cites_doi | 10.1080/15548627.2016.1231494 10.1186/s13256-023-03891-4 10.3389/fphar.2022.934746 10.1038/s41429-021-00491-6 10.1186/s13046-019-1251-7 10.1200/JCO.21.01728 10.1056/NEJMoa2115869 10.1016/j.nmni.2021.100924 10.3390/ph18010014 10.1016/j.jinf.2024.106130 10.2183/pjab.87.13 10.3390/diseases11010049 10.1016/j.ygyno.2021.12.031 10.1002/prp2.954 10.1080/15563650.2022.2043338 10.1177/0018578718758972 10.1001/jama.2023.1650 10.1007/s00204-021-03025-z 10.1016/j.amjms.2019.11.001 10.1377/hlthaff.2024.00452 |
| ContentType | Journal Article |
| Copyright | 2025 The Authors |
| Copyright_xml | – notice: 2025 The Authors |
| DBID | 6I. AAFTH AAYXX CITATION DOA |
| DOI | 10.1016/j.gore.2025.101803 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2352-5789 |
| ExternalDocumentID | oai_doaj_org_article_a965613b1ae4482b820ddf1b881751ca 10_1016_j_gore_2025_101803 S2352578925001286 |
| GroupedDBID | .1- .FO 1P~ 457 53G 5VS AAEDT AAEDW AAIKJ AALRI AAXUO AAYWO ABMAC ACGFS ACVFH ADBBV ADCNI ADEZE ADRAZ ADVLN AEUPX AEVXI AEXQZ AFJKZ AFPUW AFRHN AFTJW AGHFR AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BCNDV EBS EJD FDB GROUPED_DOAJ HYE IPNFZ KQ8 M41 M48 M~E OK1 PH~ RIG ROL RPM SSZ Z5R 6I. AAFTH AAYXX CITATION |
| ID | FETCH-LOGICAL-c342t-81f4534b4f0944e049760cf4eb0bd833754bdd1449e4284bb45bd80bcc0da1593 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001540337800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2352-5789 |
| IngestDate | Fri Oct 03 12:43:51 EDT 2025 Sat Nov 29 07:38:48 EST 2025 Sat Sep 20 17:14:43 EDT 2025 Sat Sep 20 06:21:15 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 Gynecologic cancers Wonder drug Anti-helminthic Ivermectin |
| Language | English |
| License | This is an open access article under the CC BY license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c342t-81f4534b4f0944e049760cf4eb0bd833754bdd1449e4284bb45bd80bcc0da1593 |
| ORCID | 0000-0001-5687-6667 |
| OpenAccessLink | https://doaj.org/article/a965613b1ae4482b820ddf1b881751ca |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a965613b1ae4482b820ddf1b881751ca crossref_primary_10_1016_j_gore_2025_101803 elsevier_sciencedirect_doi_10_1016_j_gore_2025_101803 elsevier_clinicalkey_doi_10_1016_j_gore_2025_101803 |
| PublicationCentury | 2000 |
| PublicationDate | August 2025 2025-08-00 2025-08-01 |
| PublicationDateYYYYMMDD | 2025-08-01 |
| PublicationDate_xml | – month: 08 year: 2025 text: August 2025 |
| PublicationDecade | 2020 |
| PublicationTitle | Gynecologic oncology reports |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Crump, Ōmura (b0025) 2011; 87 Jawad, Richardson (b0060) 2023; 11 Santin, Scheim, McCullough, Yagisawa, Borody (b0120) 2021; 43 Rockwell, Vangala, Hadfield, Cantor, Skinner, Craff, Fendrick, Damberg, Kahn, Mafi (b0115) 2025; 44 Johnson-Arbor (b0070) 2022; 60 (Accessed 29 May 2025). Lee, Kang, Kim, Kim, Jeong, Hong, Fang, Kim, Lee, Kim, Park (b0080) 2022; 13 U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Sklice NDA 202736. Retrieved May 18, 2025 “Find NCI-Supported Clinical Trials.” National Cancer Institute Zaidi, Dehgani-Mobaraki (b0150) 2022; 75 Slomovitz, Filiaci, Walker, Taub, Finkelstein, Moroney, Fleury, Muller, Holman, Copeland, Miller, Coleman (b0125) 2022; 164 Donfo-Azafack, Nana-Djeunga, Wafeu-Sadeu, Dongmo-Yemele, Kamgno (b0030) 2023; 17 Wagner, Ravi, Riedel, Ganjoo, Van Tine, Chugh, Cranmer, Gordon, Hornick, Du, Grigorian, Schmid, Hou, Harris, Kwiatkowski, Desai, Dickson (b0140) 2021; 39 Lawrence, L. Interest in Ivermectin for Cancer ‘Has Spread like Wildfire,’ Oncologists Say, Published June 13, 2025, (Accessed July 5, 2025) Dy, Juangco (b0035) 2023; 15 Office for Human Research Protections (OHRP). “45 CFR 46.” Zhang, Qin, Zhu, Hong, Xu, Zhang, Xu, Ma (b0155) 2020; 359 Naggie, Boulware, Lindsell, Stewart, Slandzicki, Lim, Cohen, Kavtaradze, Amon, Gabriel, Gentile, Felker, Jayaweera, McCarthy, Sulkowski, Rothman, Wilson, DeLong, Remaly, Investigators (b0090) 2023; 329 Wang, Wei, Qianhui, Haining, Qifu, E., Huang (b0145) 2016; 12 Gilbert, Slechta (b0045) 2018; 53 Rendic (b0110) 2021; 95 . Reis, Silva, Silva, Thabane, Milagres, Ferreira, Dos Santos, Campos, Nogueira, de Almeida, Callegari, Neto, Savassi, Simplicio, Ribeiro, Oliveira, Harari, Forrest, Ruton, Mills (b0105) 2022; 386 Nunes, Ricardo (b0095) 2024; 18 Jiang, Wang, Sun, Wu (b0065) 2019; 38 Hayward, Yu, Little, Gbinigie, Shanyinde, Harris, Dorward, Saville, Berry, Evans, Thomas, Patel, Richards, Hecke, Detry, Saunders, Fitzgerald, Robinson, Latimer-Bell, Butler (b0055) 2024; 88 12 Feb. 2025 A Phase I/Ii Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer with Expansion Cohort in Pd-L1 Negative Tnbc. Translated by Inc Agenus and Research Gateway for Cancer, 2022. Accessed May 18, 2025. Blum, D. What Ivermectin Can (and Can’t) Do. The New York Times , Published March 31 2025, Accessed June 5, 2025. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. ANDA NDA 204154. Retrieved May 18, 2025 Lu, Zhou, Zuo, Le, Hu, Zhang, Li, Yuan (b0085) 2022; 10 U.S. Food and Drug Administration. Ivermectin and COVID-19. Published April 5, 2024, Accessed May 18, 2025. Mayo Clinic. Ivermectin (Oral Route) Description and Brand Names - Mayo Clinic. www.mayoclinic.org. Published February 1, 2025. Accessed May 18, 2025. Hashimoto, Messerli, Sudo, Maruta (b0050) 2009; 3 Dy (10.1016/j.gore.2025.101803_b0035) 2023; 15 Slomovitz (10.1016/j.gore.2025.101803_b0125) 2022; 164 Nunes (10.1016/j.gore.2025.101803_b0095) 2024; 18 Zaidi (10.1016/j.gore.2025.101803_b0150) 2022; 75 Crump (10.1016/j.gore.2025.101803_b0025) 2011; 87 Hashimoto (10.1016/j.gore.2025.101803_b0050) 2009; 3 Hayward (10.1016/j.gore.2025.101803_b0055) 2024; 88 Wagner (10.1016/j.gore.2025.101803_b0140) 2021; 39 10.1016/j.gore.2025.101803_b0135 Jawad (10.1016/j.gore.2025.101803_b0060) 2023; 11 10.1016/j.gore.2025.101803_b0015 Rendic (10.1016/j.gore.2025.101803_b0110) 2021; 95 Wang (10.1016/j.gore.2025.101803_b0145) 2016; 12 10.1016/j.gore.2025.101803_b0010 Johnson-Arbor (10.1016/j.gore.2025.101803_b0070) 2022; 60 10.1016/j.gore.2025.101803_b0075 10.1016/j.gore.2025.101803_b0130 Jiang (10.1016/j.gore.2025.101803_b0065) 2019; 38 Lee (10.1016/j.gore.2025.101803_b0080) 2022; 13 Donfo-Azafack (10.1016/j.gore.2025.101803_b0030) 2023; 17 Zhang (10.1016/j.gore.2025.101803_b0155) 2020; 359 Lu (10.1016/j.gore.2025.101803_b0085) 2022; 10 Reis (10.1016/j.gore.2025.101803_b0105) 2022; 386 Gilbert (10.1016/j.gore.2025.101803_b0045) 2018; 53 Santin (10.1016/j.gore.2025.101803_b0120) 2021; 43 Naggie (10.1016/j.gore.2025.101803_b0090) 2023; 329 10.1016/j.gore.2025.101803_b0005 10.1016/j.gore.2025.101803_b0020 10.1016/j.gore.2025.101803_b0100 Rockwell (10.1016/j.gore.2025.101803_b0115) 2025; 44 10.1016/j.gore.2025.101803_b0040 |
| References_xml | – reference: “Find NCI-Supported Clinical Trials.” National Cancer Institute , – volume: 95 start-page: 1535 year: 2021 end-page: 1546 ident: b0110 article-title: Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects publication-title: Arch. Toxicol. – reference: Mayo Clinic. Ivermectin (Oral Route) Description and Brand Names - Mayo Clinic. www.mayoclinic.org. Published February 1, 2025. Accessed May 18, 2025. – volume: 88 year: 2024 ident: b0055 article-title: Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes publication-title: J. Infect. – volume: 87 start-page: 13 year: 2011 end-page: 28 ident: b0025 article-title: Ivermectin, 'wonder drug' from Japan: the human use perspective publication-title: Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. – volume: 53 start-page: 393 year: 2018 end-page: 394 ident: b0045 article-title: A case of ivermectin-induced warfarin toxicity: first published report publication-title: Hosp. Pharm. – volume: 11 year: 2023 ident: b0060 article-title: Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells publication-title: Diseases – volume: 10 year: 2022 ident: b0085 article-title: Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways publication-title: Pharmacol. Res. Perspect. – volume: 329 start-page: 888 year: 2023 end-page: 897 ident: b0090 article-title: Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial publication-title: JAMA – reference: Lawrence, L. Interest in Ivermectin for Cancer ‘Has Spread like Wildfire,’ Oncologists Say, Published June 13, 2025, (Accessed July 5, 2025) – reference: U.S. Food and Drug Administration, Center for Drug Evaluation and Research. ANDA NDA 204154. Retrieved May 18, 2025, – volume: 12 start-page: 2498 year: 2016 end-page: 2499 ident: b0145 article-title: Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer publication-title: Autophagy – volume: 15 year: 2023 ident: b0035 article-title: Identifying the toxidrome of ivermectin toxicity publication-title: Cureus – volume: 17 start-page: 141 year: 2023 ident: b0030 article-title: Successful management of poisoning with ivermectin (Mectizan) in the Obala health district (Centre Region, Cameroon): a case report publication-title: J. Med. Case Reports – reference: U.S. Food and Drug Administration. Ivermectin and COVID-19. Published April 5, 2024, Accessed May 18, 2025. – volume: 60 start-page: 571 year: 2022 end-page: 575 ident: b0070 article-title: Ivermectin: a mini-review publication-title: Clin. Toxicol. (Phila.) – reference: . (Accessed 29 May 2025). – volume: 13 year: 2022 ident: b0080 article-title: Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction publication-title: Front. Pharmacol. – volume: 43 year: 2021 ident: b0120 article-title: Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19 publication-title: New Microb. New Infect. – volume: 39 start-page: 3660 year: 2021 end-page: 3670 ident: b0140 article-title: nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors publication-title: J. Clin. Oncol. – volume: 44 start-page: 246 year: 2025 end-page: 255 ident: b0115 article-title: Demographic variation In US outpatient hydroxychloroquine and ivermectin use during the COVID-19 pandemic publication-title: Health Aff (millwood) – reference: U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Sklice NDA 202736. Retrieved May 18, 2025, – volume: 3 start-page: 243 year: 2009 end-page: 246 ident: b0050 article-title: Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines publication-title: Drug. Discov. Ther. – reference: , 12 Feb. 2025, – volume: 386 start-page: 1721 year: 2022 end-page: 1731 ident: b0105 article-title: Effect of early treatment with ivermectin among patients with Covid-19 publication-title: N. Engl. J. Med. – reference: A Phase I/Ii Study Evaluating the Safety and Efficacy of Ivermectin in Combination with Balstilimab in Patients with Metastatic Triple Negative Breast Cancer with Expansion Cohort in Pd-L1 Negative Tnbc. Translated by Inc Agenus and Research Gateway for Cancer, 2022. Accessed May 18, 2025. – volume: 75 start-page: 60 year: 2022 end-page: 71 ident: b0150 article-title: The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review publication-title: J. Antibiot. – reference: . – volume: 164 start-page: 481 year: 2022 end-page: 491 ident: b0125 article-title: A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study publication-title: Gynecol. Oncol. – volume: 359 start-page: 123 year: 2020 end-page: 129 ident: b0155 article-title: Ivermectin augments the in vitro and in vivo efficacy of cisplatin in epithelial ovarian cancer by suppressing Akt/mTOR signaling publication-title: Am. J. Med. Sci. – volume: 38 start-page: 265 year: 2019 ident: b0065 article-title: Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway publication-title: J. Exp. Clin. Cancer Res. – reference: Blum, D. What Ivermectin Can (and Can’t) Do. The New York Times , Published March 31 2025, Accessed June 5, 2025. – reference: Office for Human Research Protections (OHRP). “45 CFR 46.” – volume: 18 year: 2024 ident: b0095 article-title: Ivermectin strengthens paclitaxel effectiveness in high-grade serous carcinoma in 3D cell cultures publication-title: Pharmaceuticals (Basel) – ident: 10.1016/j.gore.2025.101803_b0020 – ident: 10.1016/j.gore.2025.101803_b0100 – volume: 12 start-page: 2498 issue: 12 year: 2016 ident: 10.1016/j.gore.2025.101803_b0145 article-title: Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer publication-title: Autophagy doi: 10.1080/15548627.2016.1231494 – volume: 17 start-page: 141 issue: 1 year: 2023 ident: 10.1016/j.gore.2025.101803_b0030 article-title: Successful management of poisoning with ivermectin (Mectizan) in the Obala health district (Centre Region, Cameroon): a case report publication-title: J. Med. Case Reports doi: 10.1186/s13256-023-03891-4 – volume: 13 year: 2022 ident: 10.1016/j.gore.2025.101803_b0080 article-title: Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction publication-title: Front. Pharmacol. doi: 10.3389/fphar.2022.934746 – volume: 75 start-page: 60 issue: 2 year: 2022 ident: 10.1016/j.gore.2025.101803_b0150 article-title: The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review publication-title: J. Antibiot. doi: 10.1038/s41429-021-00491-6 – volume: 38 start-page: 265 issue: 1 year: 2019 ident: 10.1016/j.gore.2025.101803_b0065 article-title: Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway publication-title: J. Exp. Clin. Cancer Res. doi: 10.1186/s13046-019-1251-7 – volume: 39 start-page: 3660 issue: 33 year: 2021 ident: 10.1016/j.gore.2025.101803_b0140 article-title: nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors publication-title: J. Clin. Oncol. doi: 10.1200/JCO.21.01728 – ident: 10.1016/j.gore.2025.101803_b0005 – ident: 10.1016/j.gore.2025.101803_b0135 – volume: 386 start-page: 1721 issue: 18 year: 2022 ident: 10.1016/j.gore.2025.101803_b0105 article-title: Effect of early treatment with ivermectin among patients with Covid-19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2115869 – volume: 43 year: 2021 ident: 10.1016/j.gore.2025.101803_b0120 article-title: Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19 publication-title: New Microb. New Infect. doi: 10.1016/j.nmni.2021.100924 – volume: 18 issue: 1 year: 2024 ident: 10.1016/j.gore.2025.101803_b0095 article-title: Ivermectin strengthens paclitaxel effectiveness in high-grade serous carcinoma in 3D cell cultures publication-title: Pharmaceuticals (Basel) doi: 10.3390/ph18010014 – volume: 88 issue: 4 year: 2024 ident: 10.1016/j.gore.2025.101803_b0055 article-title: Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes publication-title: J. Infect. doi: 10.1016/j.jinf.2024.106130 – ident: 10.1016/j.gore.2025.101803_b0015 – volume: 87 start-page: 13 issue: 2 year: 2011 ident: 10.1016/j.gore.2025.101803_b0025 article-title: Ivermectin, 'wonder drug' from Japan: the human use perspective publication-title: Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. doi: 10.2183/pjab.87.13 – volume: 11 issue: 1 year: 2023 ident: 10.1016/j.gore.2025.101803_b0060 article-title: Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells publication-title: Diseases doi: 10.3390/diseases11010049 – volume: 164 start-page: 481 issue: 3 year: 2022 ident: 10.1016/j.gore.2025.101803_b0125 article-title: A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2021.12.031 – volume: 3 start-page: 243 issue: 6 year: 2009 ident: 10.1016/j.gore.2025.101803_b0050 article-title: Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines publication-title: Drug. Discov. Ther. – ident: 10.1016/j.gore.2025.101803_b0130 – volume: 15 issue: 7 year: 2023 ident: 10.1016/j.gore.2025.101803_b0035 article-title: Identifying the toxidrome of ivermectin toxicity publication-title: Cureus – volume: 10 issue: 3 year: 2022 ident: 10.1016/j.gore.2025.101803_b0085 article-title: Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways publication-title: Pharmacol. Res. Perspect. doi: 10.1002/prp2.954 – ident: 10.1016/j.gore.2025.101803_b0040 – volume: 60 start-page: 571 issue: 5 year: 2022 ident: 10.1016/j.gore.2025.101803_b0070 article-title: Ivermectin: a mini-review publication-title: Clin. Toxicol. (Phila.) doi: 10.1080/15563650.2022.2043338 – volume: 53 start-page: 393 issue: 6 year: 2018 ident: 10.1016/j.gore.2025.101803_b0045 article-title: A case of ivermectin-induced warfarin toxicity: first published report publication-title: Hosp. Pharm. doi: 10.1177/0018578718758972 – ident: 10.1016/j.gore.2025.101803_b0010 – volume: 329 start-page: 888 issue: 11 year: 2023 ident: 10.1016/j.gore.2025.101803_b0090 article-title: Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2023.1650 – volume: 95 start-page: 1535 issue: 5 year: 2021 ident: 10.1016/j.gore.2025.101803_b0110 article-title: Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects publication-title: Arch. Toxicol. doi: 10.1007/s00204-021-03025-z – volume: 359 start-page: 123 issue: 2 year: 2020 ident: 10.1016/j.gore.2025.101803_b0155 article-title: Ivermectin augments the in vitro and in vivo efficacy of cisplatin in epithelial ovarian cancer by suppressing Akt/mTOR signaling publication-title: Am. J. Med. Sci. doi: 10.1016/j.amjms.2019.11.001 – ident: 10.1016/j.gore.2025.101803_b0075 – volume: 44 start-page: 246 issue: 3 year: 2025 ident: 10.1016/j.gore.2025.101803_b0115 article-title: Demographic variation In US outpatient hydroxychloroquine and ivermectin use during the COVID-19 pandemic publication-title: Health Aff (millwood) doi: 10.1377/hlthaff.2024.00452 |
| SSID | ssj0001503765 |
| Score | 2.3220093 |
| SecondaryResourceType | review_article |
| Snippet | •Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and... |
| SourceID | doaj crossref elsevier |
| SourceType | Open Website Index Database Publisher |
| StartPage | 101803 |
| SubjectTerms | Anti-helminthic COVID-19 Gynecologic cancers Ivermectin Wonder drug |
| Title | Ivermectin and Gynecologic Cancer: What are the data? |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2352578925001286 https://dx.doi.org/10.1016/j.gore.2025.101803 https://doaj.org/article/a965613b1ae4482b820ddf1b881751ca |
| Volume | 60 |
| WOSCitedRecordID | wos001540337800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2352-5789 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001503765 issn: 2352-5789 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2352-5789 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001503765 issn: 2352-5789 databaseCode: M~E dateStart: 20150101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEB5kEfEiPnF9kYM3qfaRdFMvosuuCu7iQWFvIa_KClapq-DF3-6kaZd6cS9eeghNGr5JZr6hky8Ax5xL7kRd0PtlKqARJigyzXigkyi2OsqsVpWl73rjMZ9MsvvWVV-uJszLA3vgzmSWOo6rImkxk4gVRixj8khxjoEv0hU1CntZK5ny54ND3DmsPiXjC7qenCwk5vrstFKtSn5FokqwvxWQWkFmuA5rNTskl35WG7Bki01YGdX_v7eA3eLKe3E-qiCyMOT6q7Dauy_Sd_Yrz4kT4yaytASpHXEFoBfb8DgcPPRvgvriA4SIxrOARzllCVU0x-SLWiTxvTTUObUqVIYn7tZaZQymQpnF7IEqRRm2h0rr0EjkJ8kOdIrXwu4CoblmBuOw4SlyD8k47scwVXksDaXS5l04aUAQb17fQjSFX8_CQSYcZMJD1oUrh9P8TadNXTWgxURtMbHIYl1IGpRFc_wTHRYONP3z02zeqyYHPugv6Lf3H1Peh1U3pC_8O4DOrPywh7CsP2fT9_KoWnr4HH0PfgCZyNrj |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ivermectin+and+Gynecologic+Cancer%3A+What+are+the+data%3F&rft.jtitle=Gynecologic+oncology+reports&rft.au=Mujumdar%2C+Vaidehi&rft.au=Huang%2C+Marilyn&rft.au=Smith%2C+Lindsey+Chippendale&rft.au=Musa%2C+Fernanda&rft.date=2025-08-01&rft.pub=Elsevier+Inc&rft.issn=2352-5789&rft.eissn=2352-5789&rft.volume=60&rft_id=info:doi/10.1016%2Fj.gore.2025.101803&rft.externalDocID=S2352578925001286 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2352-5789&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2352-5789&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2352-5789&client=summon |